Is CytoMed Therapeutics Limited (GDTC) a Buy, Sell, or Hold?
NASDAQ : GDTC
CytoMed Therapeutics Limited
$0.99 USD
$0.11 (12.5%)
- Volume
- 22.68K
- Average Volume
- 18.89K
- Market Capitalization
- $11.71M
- P/E Ratio
- -3.16
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $3.68
- Year Low
- $0.68
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.17
Company Overview
NASDAQ
Chee Kong Choo
Biotechnology
Healthcare
GDTC
42
SG
USD
Liquidity Metrics
0.07
5.17
3.66
2.95
0.00
Sales & Valuation
$319.2K
23.51
2.30
-2.38
-0.54
Profitability
-$0.33
-$3.92M
-754.66%
-758.20%
-70.74%
-60.74%
P/E Metrics
-3.16
0.19
0.19
Analyst Price Target & Rating
1/5
1 Analysts
%
Financial Health Scores
2.89
2/9
$2.95M
$7.98M
$1.13M
-$5.69M
Key Metrics (TTM)
$13.5M
21.01
-2.56
5.17
-70.74%
-58.88%
-32.21%
-41.93%
503 days
Company Executives
| Name | Title |
|---|---|
| Tien Wee Luk | Chief Clinical Officer |
| Chee Kong Choo | Executive Chairman |
| Yoong Ying Tan | Chief Corporation Officer |
| Yvonne Goh | Chief Financial Officer |
| Jieming Zeng | Chief Scientific & Medical Officer and Director |
Poll Results
No votes yet today — be the first to share your view!
About CytoMed Therapeutics Limited (NASDAQ:GDTC) Stock
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunother ... apy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
Frequently Asked Questions
-
What is the current CytoMed Therapeutics Limited (GDTC) stock price?
-
CytoMed Therapeutics Limited(NASDAQ:GDTC) stock price is $0.99 in the last trading session. During the trading session, GDTC stock reached the peak price of $3.68 while $0.68 was the lowest point it dropped to. The percentage change in GDTC stock occurred in the recent session was 12.5% while the dollar amount for the price change in GDTC stock was $0.11.
-
GDTC's industry and sector of operation?
-
The NASDAQ listed GDTC is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of GDTC?
-
Tien Wee Luk | Chief Clinical Officer
Chee Kong Choo | Executive Chairman
Yoong Ying Tan | Chief Corporation Officer
Yvonne Goh | Chief Financial Officer
Jieming Zeng | Chief Scientific & Medical Officer and Director -
How many employees does GDTC have?
-
Number of GDTC employees currently stands at 42. GDTC operates from 1 Commonwealth Lane, No. 08-22, Singapore, CE 149544, SG.
-
Link for GDTC official website?
-
Official Website of GDTC is: https://w2.cytomed.sg
-
How do I contact GDTC?
-
GDTC could be contacted at phone #65 6250 7738 and can also be accessed through its website. GDTC operates from 1 Commonwealth Lane, No. 08-22, Singapore, CE 149544, SG.
-
How many shares of GDTC are traded daily?
-
The average number of GDTC shares traded daily for last 3 months was 18.89K.
-
What is the market cap of GDTC currently?
-
The market value of GDTC currently stands at $11.71M with its latest stock price at $0.99